IMPACT Medicom

Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this third episode, we discuss the management of peripheral neuroptathy associated with enfortumab vedotin, or EV. Our Guests: This third episode on the management of neuropathy is hosted by Dr Srikala Sridhar, Professor in the Department of Medicine at th...

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the latest updates in the treatment of CLL with Dr. Laurie Sehn, Dr. Matthew Davies, and Dr. Constantine Tam.  Our Guests: Dr. Sehn Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia and Medical Oncologi...

In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. In this episode, Dr. Davids discusses the impact of the results of the ALPINE trial for clinical...

Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides,  we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer.  Our Guests: Dr. Jessica McAlpine, a Gynaecologic Oncologist and Division Head in the Division of Gynaecologic Oncology at the University of British Columbia Dr. Mary Kinloch, a Gyna...

Live From ASH, New Orleans: In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the American Society of Hematology meeting in New Orleans.  Our Guest: Dr Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Co...

Live From ASH, New Orleans: In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA. Note: The ALPINE trial was published today in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582. Our Guest: Dr. Jennifer Brown is the D...

Welcome to our 12th episode in the precision medicine in oncology podcast series. In this episode we discuss diagnostic, prognostic and predictive biomarkers for the treatment of breast cancer. Our Guest: Our guest for this episode is Dr. David Cescon,  a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre in Toronto, Ontario, where his clinical practice is devoted to...

Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we  discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.  Our Guest: Our guest f...

In this episode, we discuss immunotherapy treatment and biomarker testing for metastatic cervical cancer.  Our Guest: Dr. James Bentley is a Professor and Head of the Department of Obstetrics and Gynecology at Dalhousie University, Halifax, Canada. Dr. Bentley is Past President of the International Federation of Cervical Pathology and Colposcopy (IFCPC) and the Society of Canadian Colposcopists (S...

In this episode of IMPACT Medicom’s podcast series on immunotherapies in Head and Neck Squamous Cell Carcinoma, we discuss the medical oncologist’s role in managing patients with HNSCC, and how immunotherapies fit in to their practice. Our Guest: Dr. Martin Smoragiewicz is a Medical Oncologist at the Odette Cancer Centre, part of Sunnybrook Health Sciences Centre in Toronto, Ontario. His clinical...

Welcome to episode 11 of our Precision Medicine in Oncology series. In this episode, we discuss the development of a pan-Canadian consensus paper on the selection and use of PARP inhibitors for first-line maintenance treatment in ovarian cancer. Our Guest: Our guest for this episode is Dr. Anna Tinker, Medical Oncologist at BC Cancer in Vancouver, Canada. Dr. Tinker is also a Clinical Associate Pr...

Welcome to the second episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of: The role of the surgical oncologist in managing patients with HNSCC How immunotherapy fits into to the surgical oncologist's practice    Our Guest: Our guest is Dr. Antoine Eskander, a head and neck surgical oncologist at S...

Welcome to the first episode of IMPACT Medicom’s podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas. This episode includes a discussion of: The role of the pathologist in the management of head and neck cancers  PD-L1 testing as a predictive biomarker for immunotherapy in HNSCC Improving the testing process for PD-L1   Our Guest: Our guest is Dr. Matthew Cecchini, Pathologis...

In this episode, we discuss the treatment of triple negative breast cancer (TNBC) with Dr. Stephen Chia. We cover: The use of immunotherapies to treat TNBC Biomarkers that can determine which patients will best respond to immunotherapies The challenges of testing for PDL-1 Our Guest: Dr. Stephen Chia is a professor in the division of medical oncology and staff medical oncologist with BC Cancer, in...

In this episode of IMPACT Medicom’s Precision Medicine in Oncology podcast series, we discuss the evolving biomarker landscape in gastrointestinal malignancies and some of the advantages and challenges of implementing and accessing biomarker testing.   Our guest: Dr. Rosalyn Juergens is a medical oncologist with clinical expertise in lung and esophageal cancer. She was on the faculty at The Johns...

Welcome to episode 9 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the second episode in a 3-part series on ovarian cancer. This episode, hosted by IMPACT Medicom’s Sarah Doucette, features a debate on whether first-line maintenance therapy with PARP inhibitors can be considered a curative strategy in patients with advanced, BRCA-mutated epithelial ovarian cancer. Our Guest...

Welcome to episode 8 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology, the first in a series of episodes focusing on ovarian cancer. In this episode, we discuss the importance of BRCA testing for patients with advanced epithelial ovarian cancer and how national initiatives have helped to improve BRCA testing standards across the country. Our Guests: Dr. Janice Kwon, Gynecologic...

In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence on treatment decisions. We also discuss somatic vs...

Welcome to episode 6 of IMPACT Medicom’s podcast series on Precision Medicine in Oncology. In this episode Dr. Gonzalez discusses testing methodology, particularly for mismatch repair deficiency, as well as potential emerging biomarkers for metastatic colorectal cancer. Our Guest: Dr. Raul Gonzalez is an Associate Professor of Pathology at Harvard Medical School and the Director of Gastrointestina...

In this episode of our podcast, we discuss the use of zanubrutinib for the treatment of Waldenstrom’s Macroglobulinemia.  Our episode discusses data from the Phase 3 ASPEN trial, comparing the efficacy and safety of zanubrutinib with ibrutinib in these patients. Our Guests Our first guest, Dr. Constantine Tam, is a Professor of Hematology at the University of Melbourne, and Consultant Hematologist...

In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss: ·       The current standards for molecular testing in metastatic colorectal cancer ·       The potential benefit of a Canadian guideline for molecular testing in metastatic colorectal cancer Our guest: Dr. Sharlene Gill is Professor of Medicine at the University of British Columbia and Medical Oncolog...

Background Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics)  Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Can...

Background Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics)  Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Can...

Renseignements généraux Le cancer du poumon est l’une des formes de cancer les plus courantes ainsi que la principale cause de décès par cancer au Canada. (Statistiques canadiennes sur le cancer, 2020). Le taux de survie des patients atteints d’un cancer du poumon est faible. La survie nette à trois ans est de 71 % pour les cas diagnostiqués au stade 1, et chute à 5 % pour les cas diagnostiqués au...

Background Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics)  Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Can...